Abstract

Novel Drug Discovery on Antibody-Drug Conjugate System

Rajkumar Halder, Scientist E, Translational Health Science and Technology Institute

As world population is growing dramatically then maintaining good individual health is a major concern. Although several treatment and/or measure have been taken into account to combat the mortality and morbidity still we are far behind to cure cancers. Cancers are among the leading causes of death worldwide, with approximately 14 million new cases in each year and it is expected to increase 70% more over the next few decades. There are good chemotherapies, which might cure and/or stop the progression of cancers but morbidity is the major concern after the treatment because currently commercially available cytotoxic drugs for the treatment of cancers can’t differentiate between normal and cancer cells. To increase the longevity and wellbeing, Antibody-Drug Conjugate (ADC) is the best system for targeted delivery to the organ, tissue and cells to cure specific cancer. It also stops relapsing and reduces the side effects. In this talk, I will be discussing a golden journey on how to develop a novel antibody-drug conjugate system through expanding genetic code and its superiority over other ADC systems. It will also be discussed on our strategies and approaches for selecting an antibody, linker, toxin/s and payload for the development of a novel A